Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

about

Metabolic effects of androgen deprivation therapy Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.

P2860

Q34962416-0AA4AF60-E1F0-465F-A7CA-5FD2250DB3F5 Q35022939-90022FFF-2D71-48F7-BD25-7D4D1B69156A

P2860

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

Item

http://www.wikidata.org/entity/Q41881479

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

@en

type

Item

label

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

@en

prefLabel

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

@en

P1476

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

@en

P2093

Mahnaz Roayaei

http://www.w3.org/2001/XMLSchema#string

Sedighe Ghasemi

http://www.w3.org/2001/XMLSchema#string

P2860

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance

Metabolic complications of androgen deprivation therapy for prostate cancer

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Ageing, hormones, body composition, metabolic effects.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Androgen deprivation therapy for prostate cancer.

The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Pathologic effects of testosterone deprivation.

P304

580-582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24516490

http://www.w3.org/2001/XMLSchema#string

P932

3897025

http://www.w3.org/2001/XMLSchema#string

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

about

P2860

P2860

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932